Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer

Generated Narrative: Group

Resource Group "179619" Version "4" Updated "2023-12-06 00:11:33+0000"

Profile: SystematicReviewEligibilityCriteria

Artifact related artifact:

Artifact Author: Brian S. Alper:

Artifact Title: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer

Artifact URL: https://fevir.net/resources/Group/179619

Artifact Publisher: Computable Publishing LLC

Artifact Copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

Artifact use context: Evidence Communication: SystematicReviewEligibilityCriteria

Artifact Contact: support@computablepublishing.com

CombinationMethod: all-of

modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]

identifier: FEvIR Object Identifier/179619

type: animal

membership: definitional

name: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer

description: **Study selection criteria** Types of Studies. Randomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone. Types of participants. Patients aged ≥18 years with cytological or histological diagnosis of mHNPC.

characteristic

CharacteristicDescription: Randomized controlled clinical trials (RCTs)

code: Study Design ()

value: randomized assignment (Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide#SEVCO:01003)

exclude: false

characteristic

CharacteristicDescription: parallel design

code: Study Design ()

value: Parallel cohort design (Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide#SEVCO:01011)

exclude: false

characteristic

CharacteristicDescription: compared the association of ADT and chemotherapy (docetaxel), versus ADT alone

code: Comparison ()

value: : GroupAssignment: ADT plus docetaxel vs. ADT alone

exclude: false

characteristic

CharacteristicDescription: Types of participants. Patients aged ≥18 years

CharacteristicMethod: applied to participants in the studies ()

code: Age (SNOMED CT#397669002)

value: >=18 years (Details: UCUM code a = 'a')

exclude: false

characteristic

CharacteristicDescription: Types of participants. Patients with cytological or histological diagnosis of mHNPC.

CharacteristicMethod: applied to participants in the studies ()

CharacteristicMethod: cytological or histological diagnosis ()

code: Disease (disorder) (SNOMED CT#64572001)

value: metastatic hormone-naive prostate cancer ()

exclude: false